What will 2015 look like for pharma?
This article was originally published in Scrip
Executive Summary
With the New Year upon us, and with our recent efforts at scrying yet be refuted (see Why Pfizer won't come back for AstraZeneca and Why wait for accountants? Get pharma's 2014 Top 20 now), this seems like the perfect time for Scrip's renowned editorial team and regular contributors to continue riding the future-gazing wave and share their expectations for 2015.